Cheri A. Stevenson - Concepedia

Author

Cheri A. Stevenson

Also Known As

Cheri A. Stevenson, Cheri Stevenson

Publications

294

Citations

H-Index

Concepts

All Affiliations

Cheri A. Stevenson is an author at Mersana Therapeutics (United States) specializing in immunotherapy, medicine, and tumor microenvironment.

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	156
2	Engineering	2	2	132
3	Biomolecular Engineering	2	2	132
4	Immunology	2	2	57
5	Biomedical Engineering	1	1	99

Cheri A. Stevenson

Publications

272

Citations

H-Index

Page 1

	Year	Citations
A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy Alexander V. Yurkovetskiy, Mao Yin, Natalya D. Bodyak, Cancer Research EngineeringSmart PolymerBiomedical EngineeringImmunotherapyProtein Nanoparticles	2015	99
Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Molecular Cancer Therapeutics	2021	70
The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Molecular Cancer Therapeutics	2021	46
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer Dorin Toader, Shawn P. Fessler, Scott D. Collins, Molecular Cancer Therapeutics EngineeringImmunologyImmunotherapeuticsImmunotherapyTumor Biology	2023	33
Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research ImmunologyImmunoeditingNovel EpitopeImmunotherapeuticsSting Agonist	2022	24

Page 1